Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
10/03/18
Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2018-- Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced it will present new data for SER-109, a microbiome candidate in Phase 3 development, at the IDWeek 2018 conference being held from October 3-7 in San Francisco, CA. The findings, highlighted in two presentations, provide support for ... 
09/04/18
Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 4, 2018-- Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced the appointment of Meryl Zausner, a seasoned biopharmaceutical executive, to its Board of Directors. Ms. Zausner brings decades of financial and operational leadership experience in the pharmaceutical industry. “Meryl Zausner is a highly accomplished financial and strategic leader, and I am delighted to welcome her to the Seres Board,” ... 
08/02/18
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
- Company preparing to initiate SER-287 Phase 2b study for ulcerative colitis - - Initiation of SER-401 clinical study expected in patients with metastatic melanoma treated with checkpoint inhibitors by year end - - Recent Seres R&D event highlighted microbiome scientific leadership across several clinical and preclinical programs - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)-... 
EventsMore
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$6.53
 - 0.09 (1.36%)
10/19/18 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.